EUS guided pancreatic duct decompression in surgically altered anatomy or failed ERCP - A systematic review, meta-analysis and meta-regression.

ERP in Surgically altered anatomy EUS guided ERP Meta-regression Metaanalysis Safety and efficacy

Journal

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
ISSN: 1424-3911
Titre abrégé: Pancreatology
Pays: Switzerland
ID NLM: 100966936

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 26 11 2020
revised: 28 03 2021
accepted: 29 03 2021
pubmed: 19 4 2021
medline: 6 1 2022
entrez: 18 4 2021
Statut: ppublish

Résumé

EUS-PD (EUS guided pancreatic duct drainage) is classified into two types: EUS-guided rendezvous techniques and EUS-guided PD stenting. Prior studies showed significant variation in terms of technical success, clinical success and adverse events. Three independent reviewers performed a comprehensive review of all original articles published from inception to June 2020, describing pancreatic duct drainage utilizing EUS. Primary outcomes were technical success, clinical success of EUS-PDD and safety of EUS-PD in terms of adverse events. All meta-analysis and meta-regression tests were 2-tailed. Finally, probability of publication bias was assessed using funnel plots and with Egger's test. A total of sixteen studies (503 patients) described the use of EUS-PD for pancreatic duct decompression yielded a pooled technical success rate was 81.4% (95% CI 72-88.1, I 2 = 74). Meta-regression revealed that proportion of altered anatomy and method of dilation of tract explain the variance. Overall pooled clinical success rate was 84.6% (95% CI 75.4-90.8, I 2 = 50.18). Meta-regression analysis revealed that the type of pancreatic duct decompression, proportion of altered anatomy and follow up time explained the variance. Overall pooled adverse event rate was 21.3% (95% CI 16.8-26.7, I 2 = 36.6). The most common post procedure adverse event was post procedure pain. Overall pooled adverse event rate of post EUS-PD pancreatitis was 5% (95% CI 3.2-7.8, I 2 = 0). The systematic review, meta-analysis and meta-regression provides answer to the questions of the overall technical success, clinical success and the adverse event rate of EUS-PD by summarizing the available literature.

Identifiants

pubmed: 33865725
pii: S1424-3903(21)00136-8
doi: 10.1016/j.pan.2021.03.021
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

990-1000

Informations de copyright

Copyright © 2021 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Auteurs

Abhishek Bhurwal (A)

Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, United States. Electronic address: abhishek.bhurwal@gmail.com.

Augustine Tawadros (A)

Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, United States.

Hemant Mutneja (H)

Division of Gastroenterology and Hepatology, John H. Stroger Cook County Hospital, Chicago, IL, United States.

Mihajlo Gjeorgjievski (M)

Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, United States.

Ishani Shah (I)

Department of Gastroenterology, BIDMC, Boston, United States.

Vikas Bansal (V)

Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, United States.

Anish Patel (A)

Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, United States.

Avik Sarkar (A)

Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, United States.

Michal Bartel (M)

Division of Gastroenterology and Hepatology, Fox Chase Cancer Center, Philadelphia, United States.

Bhaumik Brahmbhatt (B)

Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH